Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEVAD
- Development stage
- Unknown
- Lead developer
- International Oncology Study Group
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CEVAD is a chemotherapy combination regimen consisting of cyclophosphamide, etoposide, vincristine, doxorubicin (Adriamycin), and dexamethasone. It was developed as a modification of the VAD regimen (vincristine, doxorubicin, dexamethasone) with the addition of etoposide and cyclophosphamide. This regimen works through multiple mechanisms to target rapidly dividing cancer cells, including DNA cross-linking, DNA intercalation, topoisomerase II inhibition, microtubule disruption, and immunosuppression.
- Other names
- Cyclophosphamide, Etoposide, Vincristine, Adriamycin, and Dexamethasone
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNAMicrotubule
Beyond the preview
Go deeper on CEVAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEVAD.